

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1.-59. (Canceled).

60. (New) A method for suppressing hypertrophy of the vascular intima caused by expression of tissue factor in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an antibody that binds to an inhibitory site for binding a complex of human tissue factor (human TF) and Factor VIIa to Factor X, upon binding to human TF,

wherein the antibody is a humanized antibody of version b-b, i-b, or i-b2, wherein said humanized antibody version has, respectively, the heavy and light chain pairings of SEQ ID NO: 29 and SEQ ID NO: 88 for version b-b; SEQ ID NO: 59 and SEQ ID NO: 88 for version i-b; and SEQ ID NO: 59 and SEQ ID NO: 98 for version i-b2, and wherein there is a constant region and the constant region is a constant region of human IgG.

61. (New) A method for suppressing hypertrophy of the vascular intima caused by expression of tissue factor in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an antibody that binds to an inhibitory site for binding a complex of human tissue factor (human TF) and Factor VIIa to Factor X, upon binding to human TF,

wherein the antibody is an altered antibody comprising H chains and L chains, wherein the H chain contains CDRs contained in SEQ ID NO: 59 and the L chain contains CDRs contained in SEQ ID NO: 98.

62. (New) A method for suppressing hypertrophy of the vascular intima caused by expression of tissue factor in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an antibody that binds to an inhibitory site for binding a complex of human tissue factor (human TF) and Factor VIIa to Factor X, upon binding to human TF,

wherein the antibody that binds to an inhibitory site for binding a complex of human TF and Factor VIIa to Factor X, upon binding to human TF, has CDRs which are the same as CDRs of version i-b2 antibody, wherein the version i-b2 antibody is an antibody in which variable regions have SEQ ID NO: 59 and SEQ ID NO: 98, and constant regions are of human IgG.